Apellis principal accounting officer Nicole Perry to depart Aug 30, 2021

Apellis Pharmaceuticals, Inc.

Nicole Perry will transition from principal accounting officer role effective August 30, 2021.
No successor or interim replacement has been announced.
Filing does not specify whether Perry will remain with the company in another capacity.
Reason for the departure is not disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nicole Perry

Vice President of Accounting and principal accounting officer

APLS · Apellis Pharmaceuticals, Inc.

Effective: 2021-08-30
Filed: August 19, 2021, 7:59 PM ET

On August 13, 2021, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Nicole Perry, Vice President of Accounting and principal accounting officer of the Company, agreed that she would transition from the role of principal accounting officer, effective as of August 30, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicole Perry changed role as Vice President of Accounting and principal accounting officer at Apellis Pharmaceuticals, Inc..

Action: transitioned from role
Role: Vice President of Accounting and principal accounting officer

Exact text from the filing

On August 13, 2021, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Nicole Perry, Vice President of Accounting and principal accounting officer of the Company, agreed that she would transition from the role of principal accounting officer, effective as of August 30, 2021.

View on SEC.gov

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-251478

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.